Reneo Pharmaceuticals, Inc. (RPHM) Research

Reneo Pharmaceuticals, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to creating therapies for individuals suffering from uncommon inherited mitochondrial disorders. The company's lead candidate, REN001, functions as a selective peroxisome proliferator-activated receptor delta agonist. This compound is currently undergoing Phase IIb clinical trials for patients with primary mitochondrial myopathies. Additionally, REN001 is being assessed in Phase 1b clinical trials for those diagnosed with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Founded in 2014, Reneo Pharmaceuticals' headquarters are located in San Diego, California.

Market snapshot

Symbol
RPHM
Price
$18.20
Day change
+952.02%
Market cap
$60.8M
52-week range
1.68-82.9
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Achilles Therapeutics plc (ACHL)
  • AlloVir, Inc. (ALVR)
  • Heat Biologics, Inc. (HTBX)
  • Kronos Bio, Inc. (KRON)
  • Quince Therapeutics, Inc. (QNCX)
  • Rein Therapeutics Inc. (RNTX)
  • Sigilon Therapeutics, Inc. (SGTX)
  • Surface Oncology, Inc. (SURF)

Recent insider activity

  • Leonard Braden Michael — P-Purchase (68746 shares) on 2024-09-25
  • Leonard Braden Michael — P-Purchase (29600 shares) on 2024-09-24
  • Leonard Braden Michael — P-Purchase (806 shares) on 2024-09-18
  • Leonard Braden Michael — P-Purchase (55300 shares) on 2024-09-17
  • Leonard Braden Michael — P-Purchase (172747 shares) on 2024-09-16

Open Reneo Pharmaceuticals, Inc. (RPHM) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.